The Cuban Center for Genetic Engineering and Biotechnology (CIGB) highlighted Tuesday the new clinical evidence of the safety and therapeutic effect of the national vaccine HeberSaVax, which constituted an achievement of science and innovation in the country in 2022.
On its Twitter account, the institution published the recognition granted by BioCubaFarma, to the entities executing the immunogen also known as CIGB 247, used in the treatment of hepatocellular carcinoma and ovarian cancer in advanced stages.
Recently, in a meeting of health experts and scientists with the President of the Republic, Miguel Díaz-Canel, it was reported that HeberSaVax is a safe and tolerable product, with minimal adverse reactions, which was concluded after 10 years of continuous immunizations in clinical trials.
Dr. Francisco Hernandez, who is clinically responsible for the development of CIGB 247, stated that it is a safe and less expensive Cuban therapeutic alternative compared to others existing in the world, available to patients suffering from complex health problems.
During the meeting, Enrique Arús Soler, a specialist in Gastroenterology-Hepatology and endoscopist, said that “when one sees that a median survival time of 11 months is achieved against the leading product in the world, which is Sorafenib (which does not exceed six months), there is no doubt that it is very powerful clinical evidence”, he emphasized.
Published by RHC
